Is Shree Pacetronix overvalued or undervalued?

As of 10 October 2025, the valuation grade for Shree Pacetronix has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, especially given its high PE ratio of 82.79 and an EV to EBITDA ratio of 33.42, which, while elevated, suggests potential growth relative to its peers. The ROCE stands at 8.46%, and the ROE is at 5.37%, reflecting moderate returns on capital and equity. In comparison to its peers, Shree Pacetronix's valuation appears more favorable against companies like Poly Medicure, which has a PE ratio of 53.87 and an EV to EBITDA of 40.03, and Vimta Labs, with a PE of 52.02 and an EV to EBITDA of 27.90. Furthermore, Shree Pacetronix has outperformed the Sensex significantly, with a year-to-date return of 89.52% compared to the Sensex's 5.58%. This performance reinforces the notion that the company is undervalued in the current market landscape.